WOBURN, Mass.--(BUSINESS WIRE)--Aphios Corporation today announced that it was awarded Phase I of a Fast Track SBIR grant from the National Institute on Drug Abuse (NIDA), NIH to develop a process for manufacturing cGMP cannabidiol (CBD) using its green drug manufacturing technology.
The primary goal of this research program is to develop a process for manufacturing pharmaceutical grade CBD following current Good Manufacturing Practices (cGMP) of the US FDA for use in clinical trials for Multiple Sclerosis, childhood epilepsy and other CNS indications by the NIH and other researchers. The ready availability of pharmaceutical-grade CBD, manufactured following cGMP guidelines, will facilitate clinical evaluation by NIH investigators and other researchers for epilepsy, MS and other CNS diseases. The developed process will also be utilized for the manufacturing of ?9-THC, already in use for cancer pain and nausea and AIDS-related cachexia, and other cannabinoids such as cannabigerol (CBG) in development.
Help employers find you! Check out all the jobs and post your resume.
